製品番号: HY-N0551

Wedelolactone

25 Cited Publications

カスタマーレビュー

Based on 25 publication(s) in Google Scholar

Wedelolactone suppresses LPS-induced caspase-11 expression by directly inhibits the IKK Complex. Wedelolactone also inhibits 5-lipoxygenase (5-Lox) with an IC₅₀ of 2.5 μM. Wedelolactone induces caspase-dependent apoptosis in prostate cancer cells via downregulation of PKCε without inhibiting Akt. Wedelolactone can extract from Eclipta alba, and it can be used for the research of cancer.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.87%
CAS 番号: 524-12-9
分子式: C₁₆H₁₀O₇
分子量:314.25

保管条件:

Powder -20°C, 3 years ; In solvent -80°C, 1 year , -20°C, 6 months

Wedelolactone 構造式

CAS 番号: 524-12-9

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
化学情報
Publications (25)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target^[1]^[2]^[3]

Caspase-11

5-LOX

2.5 μM (IC₅₀)

Apoptosis

Caspase アイソフォーム固有の製品をすべて表示 :

Lipoxygenase アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
OVCAR-3	EC₅₀	10.64 μM Compound: Wedelolactone	Inhibition of colony formation in human OVCAR-3 cells overexpressing G6PD incubated for 14 days by crystal violet staining based assay Inhibition of colony formation in human OVCAR-3 cells overexpressing G6PD incubated for 14 days by crystal violet staining based assay	[PMID: 33689874]
Vero	CC₅₀	373.5 μM Compound: Wedelolactone	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 38879995]

体外実験

Wedelolactone (0-5 μg/mL; 0-21 d) enhances bone marrow mesenchymal stem cells (BMSC) differentiation towards osteoblasts^[3].
Wedelolactone (0-6 μg/mL; 0-9 d) inhibits GSK3β activity and increases β-catenin and runx2 nuclear accumulation in BMSC, and inhibits the effect of RANKL^[3].
Wedelolactone (0-5 μg/ml; 60 min) inhibits GSK3β activity and proves GSK3β is the target of wedelolactone^[3].
Wedelolactone (0-5 μg/ml; 6 d) inhibits c-src, c-fos and cathepsin k expression level^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Differentiation Assay^[3]

Cell Line:

Mouse BMSC
Concentration:

0-5 μg/mL
Incubation Time:

0, 6, 9, 12 and 21 days
Result:

Increased Mouse BMSC into osteoblastic cells and dose-dependently increased the activity of alkaline phosphatase at incubation for 9 days.

Western Blot Analysis^[3]

Cell Line:

Mouse BMSC and RAW264.7 cells
Concentration:

0-5 μg/mL
Incubation Time:

0-9 days
Result:

Decreased GSK3β expression level and up-regulated GSK3β phosphorylation, nuclear accumulation of β-catenin and runx2 in BMSC. Inhibited RANKL-induced phosphorylation of NF-κB/p65 and the expression level of c-fos and c-Src.

Cell Viability Assay^[3]

Cell Line:

Mouse BMSC
Concentration:

0.1, 1.25, 2.5, 5 μg/ml
Incubation Time:

60 min
Result:

Inhibited GSK3β activity with an IC₅₀ of 21.7 μM weeker than staurosporin which is a GSK3β inhibitor and proved GSK3β is a target.

RT-PCR^[3]

Cell Line:

RAW264.7 cells
Concentration:

0, 0.6, 1.25, 2.5 and 5 μg/mL
Incubation Time:

6 days
Result:

Inhibited the expression of osteoclast differentiation related marker genes c-src, c-fos and cathepsin in RAW264.7 cells.

体内実験

Wedelolactone (10 mg/kg; i.p. every 2 days for 4 weeks) decreases bone volumn and trabecular number at the femur after ovarietomy, and prevents the VOX-induced bone loss^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Ovariectomized 9-week-old mice^[3]
Dosage:

10 mg/kg
Administration:

Intraperitoneal injection; 10 mg/kg every 2 days; for 4 weeks
Result:

Inhibited osteoclast activity and stimulated osteoblast differentiation to achieved osteoprotective effect.

化学情報

CAS 番号 524-12-9
性状 Solid
分子量 314.25
分子式 C₁₆H₁₀O₇
Color White to light yellow
SMILES

O=C1C2=C(OC3=CC(O)=C(O)C=C32)C4=C(O)C=C(OC)C=C4O1
Structure Classification
- Phenols
- Polyphenols
Initial Source
- Plants
- Compositae
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (25)

All Bio/Physico-chemical AssayCell Proliferation/Viability AssayFlow CytometryIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

J Hematol Oncol

Allosteric activation of the metabolic enzyme GPD1 inhibits bladder cancer growth via the lysoPC-PAFR-TRPV2 axis. [Abstract]

2022 Jul 14;15(1):93. PMID: 35836291

Wedelolactone purchased from MedChemExpress. Usage Cited in: J Hematol Oncol. 2022 Jul 14;15(1):93. [Abstract]

Wedelolactone (WE) had substantial activity in activating the catalytic activity of GPD1.

Wedelolactone purchased from MedChemExpress. Usage Cited in: J Hematol Oncol. 2022 Jul 14;15(1):93. [Abstract]

The results showed that the binding affinity for Wedelolactone (WE) had a dissociation constant (K_d) of 505 nM.

Wedelolactone purchased from MedChemExpress. Usage Cited in: J Hematol Oncol. 2022 Jul 14;15(1):93. [Abstract]

Wedelolactone (WE) on the catalytic activity of GPD1 in bladder cell lines, we monitored G3P and NAD⁺ levels in the 5637 and T24 cell lines after WE treatment. We found that WE increased both G3P and NAD⁺ at a concentration of 10 µM.

Wedelolactone purchased from MedChemExpress. Usage Cited in: J Hematol Oncol. 2022 Jul 14;15(1):93. [Abstract]

To further investigate the function of WE in bladder cancer, we assessed the growth and death of bladder cancer cells after Wedelolactone (WE) treatment. Our results showed that WE reduced the proliferation ability of 5637 and T24 cells by CCK-8 cell assay, while other compounds found in virtual screening did not affect proliferation.

Wedelolactone purchased from MedChemExpress. Usage Cited in: J Hematol Oncol. 2022 Jul 14;15(1):93. [Abstract]

The colony formation assay indicated that Wedelolactone (WE) significantly decreased the colony number of 5637 cells and T24 cells.

Wedelolactone purchased from MedChemExpress. Usage Cited in: J Hematol Oncol. 2022 Jul 14;15(1):93. [Abstract]

Wedelolactone (WE) induced apoptosis in 5637 cells and T24 cells.

Wedelolactone purchased from MedChemExpress. Usage Cited in: J Hematol Oncol. 2022 Jul 14;15(1):93. [Abstract]

To determine whether Wedelolactone (WE) might suppress bladder cells in vivo, we implanted 5637 cells or T24 cells into BALB/c Nude mice. Compared with the control group, Wedelolactone (WE) treatment significantly reduced tumor weight.
Acta Pharm Sin B

Inhibition of gasdermin D-dependent pyroptosis attenuates the progression of silica-induced pulmonary inflammation and fibrosis. [Abstract]

2022 Mar;12(3):1213-1224. PMID: 35530143
Phytomedicine

Wedelolactone alleviates cholestatic liver injury by regulating FXR-bile acid-NF-κB/NRF2 axis to reduce bile acid accumulation and its subsequent inflammation and oxidative stress. [Abstract]

2024 Jan:122:155124. PMID: 38014837
Microbiol Res

Caspase-4/11-mediated non-canonical pyroptosis disrupts blood-brain barrier integrity via VEGFA/VEGFR2 signaling in Escherichia coli meningitis. [Abstract]

2026 Aug:309:128531. PMID: 42034039
Cell Rep

Inappropriate use of antibiotics exacerbates inflammation through OMV-induced pyroptosis in MDR Klebsiella pneumoniae infection. [Abstract]

2021 Sep 21;36(12):109750. PMID: 34551309
Microb Biotechnol

Peptide MSI-1 inhibited MCR-1 and regulated outer membrane vesicles to combat immune evasion of Escherichia coli. [Abstract]

2023 Sep;16(9):1755-1773. PMID: 37329166
Hepatol Commun

Gasdermin D-mediated pyroptosis suppresses liver regeneration after 70% partial hepatectomy. [Abstract]

2022 Sep;6(9):2340-2353. PMID: 35509206
Eur J Pharmacol

GSK-3β-mediated activation of NLRP3 inflammasome leads to pyroptosis and apoptosis of rat cardiomyocytes and fibroblasts. [Abstract]

2022 Apr 5;920:174830. PMID: 35182545
Int Immunopharmacol

Wedelolactone alleviates inflammation and cartilage degeneration by suppressing the NF-κB signaling pathway in osteoarthritis. [Abstract]

2024 Oct 9;143(Pt 1):113359. PMID: 39388895
Inflammation

ZAKα Induces Pyroptosis of Colonic Epithelium Via the Caspase-11/GSDMD Pathway to Aggravate Colitis. [Abstract]

2025 Feb 24. PMID: 39992609
Mediators Inflamm

2024 Sep 04.
J Cell Mol Med

TGFBI Inhibits the Pyroptosis of Macrophages to Ameliorate Septic Shock. [Abstract]

2025 Oct;29(19):e70802. PMID: 41078093
Drug Dev Res

The mechanism of Arhalofenate in alleviating hyperuricemia-Activating PPARγ thereby reducing caspase-1 activity. [Abstract]

2020 Nov;81(7):859-866. PMID: 32506648
J Virol

Enterovirus 71 infection induces pyroptotic brain injury via synergistic activation of classical inflammasome and viral gasdermin D cleavage. [Abstract]

2025 Nov 25:e0186025. PMID: 41288075
J Pharm Pharmacol

Wedelolactone suppresses breast cancer growth and metastasis via regulating TGF-β1/Smad signaling pathway. [Abstract]

2024 Jun 7:rgae065. PMID: 38848454
Immun Inflamm Dis

Pyroptosis and polarization of macrophages in septic acute lung injury induced by lipopolysaccharide in mice. [Abstract]

2024 Mar;12(3):e1197. PMID: 38501547
Chem Biol Drug Des

Comprehensive Analysis of NADH:Ubiquinone Oxidoreductase Subunit B3 in Gynecological Tumors and Identification of Its Natural Inhibitor Wedelolactone. [Abstract]

2024 Oct;104(4):e70006. PMID: 39469770
Front Neurol

Temporal and Spatial Dynamics of Inflammasome Activation After Ischemic Stroke. [Abstract]

2021 Apr 22:12:621555. PMID: 33967935
J Invest Surg

Inhibition of Caspase-11-Mediated Pyroptosis Alleviates Acute Kidney Injury Associated with Severe Acute Pancreatitis in Rats. [Abstract]

2023 Dec;36(1):1-7. PMID: 36350036
Exp Ther Med

Tetracaine hydrochloride induces macrophage pyroptosis through caspase‑1/11‑GSDMD signaling pathways. [Abstract]

2023 Jul 19;26(3):428. PMID: 37602302
Medicine

Network pharmacology-based strategy for predicting therapy targets of Ecliptae Herba on breast cancer. [Abstract]

2023 Oct 13;102(41):e35384. PMID: 37832105
J Int Med Res

Roles of the pyroptosis signaling pathway in a sepsis-associated encephalopathy cell model. [Abstract]

2020 Aug;48(8):300060520949767. PMID: 32865056
Res Sq

2026 Mar 5.
bioRxiv

2025 July 11.
Evid Based Complement Alternat Med

Pharmacological Mechanisms Underlying the Hepatoprotective Effects of Ecliptae herba on Hepatocellular Carcinoma. [Abstract]

2021 Jul 16:2021:5591402. PMID: 34326886

溶剤 & 溶解度

体外:

DMSO : 125 mg/mL (397.77 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.1822 mL

15.9109 mL

31.8218 mL

5 mM

0.6364 mL

3.1822 mL

6.3644 mL

10 mM

0.3182 mL

1.5911 mL

3.1822 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (6.62 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (6.62 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (283 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Kobori M, et al. Wedelolactone suppresses LPS-induced caspase-11 expression by directly inhibiting the IKK complex. Cell Death Differ. 2004 Jan;11(1):123-30. [Content Brief]

[2]. Sarveswaran S, et al. Wedelolactone, a medicinal plant-derived coumestan, induces caspase-dependent apoptosis in prostate cancer cells via downregulation of PKCε without inhibiting Akt. Int J Oncol. 2012 Dec;41(6):2191-9. [Content Brief]

[3]. Liu YQ, et al. Wedelolactone enhances osteoblastogenesis by regulating Wnt/β-catenin signaling pathway but suppresses osteoclastogenesis by NF-κB/c-fos/NFATc1 pathway. Sci Rep. 2016 Aug 25;6:32260. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.1822 mL	15.9109 mL	31.8218 mL	79.5545 mL
	5 mM	0.6364 mL	3.1822 mL	6.3644 mL	15.9109 mL
	10 mM	0.3182 mL	1.5911 mL	3.1822 mL	7.9554 mL
	15 mM	0.2121 mL	1.0607 mL	2.1215 mL	5.3036 mL
	20 mM	0.1591 mL	0.7955 mL	1.5911 mL	3.9777 mL
	25 mM	0.1273 mL	0.6364 mL	1.2729 mL	3.1822 mL
	30 mM	0.1061 mL	0.5304 mL	1.0607 mL	2.6518 mL
	40 mM	0.0796 mL	0.3978 mL	0.7955 mL	1.9889 mL
	50 mM	0.0636 mL	0.3182 mL	0.6364 mL	1.5911 mL
	60 mM	0.0530 mL	0.2652 mL	0.5304 mL	1.3259 mL
	80 mM	0.0398 mL	0.1989 mL	0.3978 mL	0.9944 mL
	100 mM	0.0318 mL	0.1591 mL	0.3182 mL	0.7955 mL

Keywords

Wedelolactone

25 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Wedelolactone

Multi-Target Compound Library

Bioactive Compound Library Max

Natural Product Library Plus

Bioactive Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Mass Spectrometry Natural Product Library

Natural Product and Natural Product-Like Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Natural Product Library

Anti-Cancer Compound Library

Lipid Compound Library

Ferroptosis Compound Library

Medicine Food Homology Compound Library

Phenols Library

Pyroptosis Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Lipid Metabolism Compound Library

Targeted Diversity Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Protease Inhibitor Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

MedChemExpress（MCE）の使用を引用している文献 Wedelolactone

Caspase アイソフォーム固有の製品をすべて表示

Lipoxygenase アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (25)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Wedelolactone 関連分類

HY-N0551 関連分類